Bahl & Gaynor Inc. Reduces Stock Holdings in Eli Lilly and Company $LLY

Bahl & Gaynor trimmed its Eli Lilly stake by 1.5% in Q2 to 831,489 shares (~$648.2m), leaving the drugmaker as its fifth-largest holding, while a range of other institutions materially increased or initiated positions and institutional ownership stands at 82.5%. Lilly reported a strong quarter—EPS $7.02 versus $6.42 consensus and revenue $17.60bn (up 53.9% y/y) — and set FY‑2025 EPS guidance of $23.00–$23.70 (street at ~23.48), underpinning a roughly $1.0tn market capitalization and a premium valuation (PE 69.15, PEG 1.21). Several analysts have raised targets and ratings (price targets raised into the $948–$1,165 range and multiple upgrades to outperform/strong‑buy), the stock is trading near its 52‑week high (~$1,058 open) and Lilly also declared a $1.50 quarterly dividend (0.6% yield), signaling continued institutional confidence despite rich multiples.

Analysis

Bahl & Gaynor reduced its Eli Lilly holding by 1.5% in Q2 to 831,489 shares (valued at $648,171,000), leaving LLY as its fifth-largest position at 3.3% of the portfolio; institutional ownership stands at 82.53% and several other managers materially increased or initiated positions (Lazard +114.3% to 77,295 shares, Duquesne +52.5% to 94,830 shares, Family CFO initiated a small stake). This repositioning alongside broad institutional accumulation signals active rebalancing rather than a sector-wide exit.

Eli Lilly reported a strong quarter with EPS $7.02 versus $6.42 consensus and revenue $17.60bn versus $16.09bn, a 53.9% year-over-year revenue increase, and set FY2025 guidance of $23.00–$23.70 (street ~23.48); profitability markers include ROE 92.72% and net margin 25.91%. The stock trades at a premium (market cap ~$1.0tn, PE 69.15, PEG 1.21) and is above its 50‑day ($855.89) and 200‑day ($787.66) moving averages, reflecting elevated expectations for continued growth.

Analyst sentiment is positive with multiple target upgrades (examples: BMO to $1,100, Scotiabank $1,165, CICC to $1,060) and a MarketBeat consensus target of $1,027.95; the shares opened at $1,058.05 (+1.4%) and the company declared a $1.50 quarterly dividend (annualized $6.00, yield 0.6%, payout ratio 29.35%). The combination of strong fundamentals and heavy institutional ownership supports near-term upside, but the high valuation increases sensitivity to execution risk and any downward revision to guidance.

Key Decisions for Investors

• Investors should consider maintaining core exposure to LLY given the quarter’s beat, 53.9% revenue growth and FY25 guidance in line with estimates, while acknowledging the premium valuation
• Scale into additional positions on weakness toward the 50‑day (~$855.89) or 200‑day (~$787.66) moving averages to lower entry valuation given a PE of 69.15 and $1.0tn market cap
• Monitor upcoming quarterly results, guidance execution and margin trends closely as primary catalysts that can validate or unwind the current premium multiple
• Trim or hedge outsized positions on strength or set target sell levels near recent highs since the stock trades near its 52‑week high and consensus target (~$1,027.95) is close to current price